Peptron (XKRX:087010) Retained Earnings : ₩864 Mil (As of Mar. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Peptron Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Peptron's retained earnings for the quarter that ended in Mar. 2024 was ₩864 Mil.

Peptron's quarterly retained earnings declined from Sep. 2023 (₩7,546 Mil) to Dec. 2023 (₩4,895 Mil) and declined from Dec. 2023 (₩4,895 Mil) to Mar. 2024 (₩864 Mil).

Peptron's annual retained earnings increased from Dec. 2021 (₩-82,054 Mil) to Dec. 2022 (₩20,206 Mil) but then declined from Dec. 2022 (₩20,206 Mil) to Dec. 2023 (₩4,895 Mil).

Peptron Retained Earnings Historical Data

The historical data trend for Peptron's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Peptron Retained Earnings Chart

Peptron Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Retained Earnings

Get a 7-Day Free Trial

-48,526.26

-67,073.89

-82,054.31

20,206.01

4,894.98

Peptron Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Retained Earnings	Get a 7-Day Free Trial															16,194.38	11,550.47	7,546.11	4,894.98	864.33

Peptron Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Peptron (XKRX:087010) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

Peptron (XKRX:087010) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Peptron Inc (XKRX:087010) » Definitions » Retained Earnings

Comparable Companies

Traded in Other Exchanges

N/A

Address

37-24, Yuseong-daero 1628 beon-gil, Yuseong-gu, Daejeon, KOR, 305811

Website

http://www.peptron.com

Peptron Inc is a biotechnology company engaged in developing fundamental technologies for peptide-based medicines. Its technology includes PeptrEX and SmartDepot. PeptrEX is an automatic system, enabling to synthesize simultaneously from a few to hundred types of peptides. SmartDepot is a proprietary ultrasonic spray drying technology for the preparation of sustained release injectable microsphere formulation of the drug. The group's research and development products include Luphere Depot for the treatment of prostate cancer and endometriosis, SR Exenatide PT302 AND SR EXENATIDE PT304 for the treatment of type II diabetes, SR Exenatide PT320 and 330 for the treatment of Parkinson's and Alzheimer's disease and SR Octreotide for the treatment of acromegaly and carcinoid tumor.

Peptron (XKRX:087010) Headlines

No Headlines